Working… Menu

A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02142608
Recruitment Status : Completed
First Posted : May 20, 2014
Results First Posted : August 27, 2020
Last Update Posted : March 29, 2021
Information provided by (Responsible Party):
Bracco Diagnostics, Inc

Brief Summary:
Pilot study to evaluate the ability of BR55 to identify prostate cancer lesions with Gleason Score ≥7 by ultrasound molecular imaging on the basis of a visual score in comparison with histopathology results

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: BR55 Phase 1 Phase 2

Detailed Description:
This multi-centre, open label, prospective, pilot study was designed to assess the ability of BR55 to detect VEGFR2 in human prostate cancer by Ultrasound Molecular Imaging (USMI). The binding of BR55 to VEGFR2 (focal enhancement still visible after significant decrease in signal from circulating microbubbles seen) was assessed at USMI and VEGFR2 expression was to be confirmed by immunohistochemistry (IHC) analysis including VEGFR2 and CD31 staining.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Pilot Clinical Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer by Molecular Imaging of VEGFR2
Study Start Date : August 2014
Actual Primary Completion Date : July 2015
Actual Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: BR55
All patients received BR55 as a single intravenous injection at the dose of 0.03 mL/kg...
Drug: BR55
Ultrasound contrast agent

Primary Outcome Measures :
  1. Number of Lesions With Gleason Score ≥ 7 Identified by Ultrasound Molecular Imaging [ Time Frame: Within 30 minutes after administration of BR55 ]
    To assess the ability of BR55 to identify prostate cancer lesions with a Gleason score ≥ 7 using histopathology as truth standard

Secondary Outcome Measures :
  1. Number of Participants With Adverse Events [ Time Frame: 24 hours post-dose ]
    To obtain safety data in subjects administered BR55

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male, age between 50-70 years old
  • Increased Prostate-Specific Antigen (PSA) level >4 ng/mL
  • Known prostate cancer
  • Scheduled for prostatectomy not earlier than 3 days and not later than 30 days following BR55 administration (with the exception of training cases where this requirement is not applicable)
  • Provided written informed consent and willing to comply with protocol requirements

Exclusion Criteria:

  • Documented acute prostatitis or urinary tract infections
  • Known to suffer from stable angina pectoris and/or proven coronary disease, or have symptoms suspicious of coronary disease
  • History of any clinically unstable cardiac condition including class III/IV cardiac failure or right-to left shunts
  • Severe cardiac rhythm disorders within the last 7 days
  • Severe pulmonary hypertension or uncontrolled systemic hypertension or respiratory distress syndrome
  • Received a prostate biopsy procedure within 30 days before admission into the study
  • Determined by investigator to be clinically unsuitable for the study
  • Participated in a concurrent clinical trial or has participated in another clinical trial with an investigational compound within the past 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02142608

Layout table for location information
United States, California
Translational Molecular Imaging Lab
Stanford, California, United States, 94305
Service d'Imagerie Diagnostique et Interventionnelle de l'Adulte
Bordeaux, France
Sponsors and Collaborators
Bracco Diagnostics, Inc
Layout table for investigator information
Study Director: Maria Luigia Storto, M.D. Bracco Diagnostics, Inc
Layout table for additonal information
Responsible Party: Bracco Diagnostics, Inc Identifier: NCT02142608    
Other Study ID Numbers: BR55-105
First Posted: May 20, 2014    Key Record Dates
Results First Posted: August 27, 2020
Last Update Posted: March 29, 2021
Last Verified: March 2021
Keywords provided by Bracco Diagnostics, Inc:
Prostate cancer
Ultrasound Imaging
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases